A randomized controlled trial protocol assessing the effectiveness, safety and cost-effectiveness of methotrexate vs. ciclosporin in the treatment of severe atopic eczema in children: the TREatment of severe Atopic eczema Trial (TREAT)
- 28 October 2018
- journal article
- research article
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 179 (6) , 1297-1306
Abstract
Background Oral systemic immuno‐modulatory medication is regularly used off‐licence in children with severe atopic eczema. However, there is no firm evidence regarding the effectiveness, safety, cost‐effectiveness and impact on quality of life from an adequately powered randomised controlled trial (RCT) using systemic medication in children. Patients/Methods Multi‐centre, parallel group, assessor‐blind, pragmatic RCT of 36 week duration with a 24 week follow‐up period. 102 children aged 2‐16 years with moderate to severe atopic eczema, unresponsive to topical treatment will be randomised (1:1) to receive methotrexate (MTX; 0.4mg/kg per week) or ciclosporin (CyA; 4mg/kg/day). The trial has co‐primary outcomes: change from baseline to 12 weeks in Objective Severity Scoring of Atopic Dermatitis (o‐SCORAD) and time to first significant flare following treatment cessation. Analysis plan The main aims of the trial are to assess whether there is a difference in the speed of onset, effectiveness, side‐effect profile and reduction in flares post‐treatment between CyA and MTX, and, also the cost‐effectiveness of the drugs. Treatment impact on quality of life will also be examined as well as whether FLG genotype influences treatment response. In addition, the trial studies the immune‐metabolic effects of CyA and MTX. Conclusions The TREAT trial addresses important therapeutic questions, highlighted in systematic reviews and treatment guidelines for atopic eczema. The trial design is pragmatic to reflect current clinical practice.Keywords
Funding Information
- Medical Research Council (13/50/12, PB-PG-1215-20019)
- National Institute on Handicapped Research
This publication has 26 references indexed in Scilit:
- Methotrexate and azathioprine for severe atopic dermatitis: a 5-year follow-up study of a randomized controlled trialBritish Journal of Dermatology, 2018
- Prescribing practices for systemic agents in the treatment of severe pediatric atopic dermatitis in the US and Canada: The PeDRA TREAT surveyJournal of the American Academy of Dermatology, 2017
- Systemic therapies for severe atopic dermatitis in children and adultsJournal of Allergy and Clinical Immunology, 2013
- The European treatment of severe atopic eczema in children taskforce (TREAT) surveyBritish Journal of Dermatology, 2013
- Methotrexate versus cyclosporine in the treatment of severe atopic dermatitis in children: a multicenter experience from EgyptEuropean Journal of Pediatrics, 2012
- Management of difficult and severe eczema in childhoodBMJ, 2012
- A randomized trial of methotrexate versus azathioprine for severe atopic eczemaJournal of Allergy and Clinical Immunology, 2011
- Cost of Illness of Atopic Dermatitis in ChildrenPharmacoEconomics, 2003
- Are quality of family life and disease severity related in childhood atopic dermatitis?Journal of the European Academy of Dermatology and Venereology, 2002
- Severity distribution of atopic dermatitis in the community and its relationship to secondary referralBritish Journal of Dermatology, 1998